Chanisa Chotipanich

Chanisa Chotipanich

Auto-generated profile, based on publicly available information

Chanisa Chotipanich

National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Molecular Imaging
Verified
Journal Article
Open access
PDF file
CCChanisa Chotipanich
Chanisa Chotipanich
MNMonchaya Nivorn
Monchaya Nivorn
AKAnchisa Kunawudhi
Anchisa Kunawudhi
CPChetsadaporn Promteangtrong
Chetsadaporn Promteangtrong
NBNatphimol Boonkawin
Natphimol Boonkawin
AJAttapon Jantarato
Attapon Jantarato
Background: The study aimed to evaluate the appropriate uptake-timing in cognitively normal individuals, mild cognitive impairment (MCI), and Alzheimer’s disease (AD) patients, using 18F-PI 2620 dynamic PET acquisition. Methods: Thirty-four MCI patients, 6 AD patients, and 24 cognitively normal individuals were enrolled in this study. A dynamic 18F-PI 2620 PET study was conducted at 30-75 minutes post-injection in these groups. Co-registration was applied between the dynamic acquisition PET and T1-weighted MRI to delineate various cortical regions. The standardized uptake value ratio (SUVR) was used for quantitative analysis. P-mod software with the Automated Anatomical Labeling (AAL)-merged atlas was employed to generate automatic volumes of interest for 11 brain regions. Results: The curves in most brain regions presented an average SUVR stability at 30-40 minutes post-injection in each group. The appropriate uptake-timing interval of 18F-PI 2620 was 30-75 minutes post injection for AD group and 30-40 minutes post injection for both cognitively normal individuals and MCI groups. Conclusion: Short uptake time around 30-40 minutes post-injection would be more comfortable and convenient for all patients, especially in those with dementia who were unable to stay motionless for long periods of scanning time in the scanner.

13 January 2022 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
DSDheeratama Siripongsatian
Dheeratama Siripongsatian
AKAnchisa Md Kunawudhi
Anchisa Md Kunawudhi
CPChetsadaporn Promteangtrong
Chetsadaporn Promteangtrong
PKPerapon Kiatkittikul
Perapon Kiatkittikul
AJAttapon Bsc Jantarato
Attapon Bsc Jantarato
CCChanisa Chotipanich
Chanisa Chotipanich
Purpose: This study aimed to investigate functional abnormalities in the brain of patients with neurological adverse effects following COVID-19 (coronavirus disease 2019) vaccination using 18F-FDG PET/MRI and 15O-water PET. Methods: Eight patients (1 man and 7 women, aged 26–47 years [median age, 36.5 years]) who experienced neurological symptoms after the first COVID-19 vaccination underwent CT, MRI, 18F-FDG PET/MRI, and 15O-water PET of the brain. After 7 days, each patient underwent a follow-up 18F-FDG PET/MRI and 15O-water PET of the brain. Imaging data were analyzed using visual and semiquantitative analyses, which included a cluster subtraction workflow (P = 0.05). Results: There was no evidence of vascular abnormalities, acute infarction, or hemorrhage on the CT or MRI scans. On the 15O-water PET images, 1 patient had mildly significant decreases in perfusion in the bilateral thalamus and bilateral cerebellum, and another patient showed a diffuse increase in perfusion in the cerebral white matter. The visual and semiquantitative analyses showed hypometabolism in the bilateral parietal lobes in all 8 patients on both the first and follow-up 18F-FDG PET/MRI scans. Metabolic changes in the bilateral cuneus were also observed during the first visit; all patients exhibited neurological symptoms. Moreover, 6 patients showed hypometabolism, and 2 patients showed hypermetabolism. Conclusion: All regions of metabolic abnormality were part of the fear network model that has been implicated in anxiety. Our study findings support the concepts of and provide evidence for the immunization stress-related response and the biopsychosocial model.

1 June 2021 in Molecular Imaging
Verified
Journal Article
Open access
PDF file
AJAttapon Jantarato
Attapon Jantarato
SVSira Vachatimanont
Sira Vachatimanont
NBNatphimol Boonkawin
Natphimol Boonkawin
SYSukanya Yaset
Sukanya Yaset
AKAnchisa Kunawudhi
Anchisa Kunawudhi
CCChanisa Chotipanich
Chanisa Chotipanich
Background. Some studies have reported the effectiveness of [18F]PI-2620 as an effective tau-binding radiotracer; however, few reports have applied semiquantitative analysis to the tracer. Therefore, this study’s aim was to perform a semiquantitative analysis of [18F]PI-2620 in individuals with normal cognition and patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Methods. Twenty-six cognitively normal (CN) subjects, 7 patients with AD, and 36 patients with MCI were enrolled. A dynamic positron emission tomography (PET) scan was performed 30–75 min postinjection. PET and T1-weighted magnetic resonance imaging scans were coregistered. The standardized uptake value ratio (SUVr) was used for semiquantitative analysis. The P-Mod software was applied to create volumes of interest. The ANOVA and post hoc Tukey HSD were used for statistical analysis. Results. In the AD group, the occipital lobe had a significantly higher mean SUVr ([ ]) than in the CN and MCI groups. Compared with the CN group, the AD group showed significantly higher mean SUVr in the fusiform gyrus ([ ] vs. [ ]), inferior temporal ([ ] vs. [ ]), parietal lobe, lingual gyrus, and precuneus regions. Similarly, the AD group demonstrated a higher mean SUVr than the MCI group in the precuneus, lingual, inferior temporal, fusiform, supramarginal, orbitofrontal, and superior temporal regions. The remaining observed regions, including the striatum, basal ganglia, thalamus, and white matter, showed a low SUVr across all groups with no statistically significant differences. Conclusion. A significantly higher mean SUVr of [18F]PI-2620 was observed in the AD group; a significant area of the brain in the AD group demonstrated tau protein deposit in concordance with Braak Stages III–V, providing useful information to differentiate AD from CN and MCI. Moreover, the low SUVr in the deep striatum and thalamus could be useful for excluding primary tauopathies.

1 July 2021 in World Journal of Nuclear Medicine
Verified
Journal Article
Open access
CCChanisa Chotipanich
Chanisa Chotipanich
STSupatporn Tepmongkol
Supatporn Tepmongkol
YWYodchanan Wongsawat
Yodchanan Wongsawat
AJAttapon Jantarato
Attapon Jantarato
Anapanasati is a core meditation of a breath-centered practice in the Buddhist Theravada tradition, which may have some neurological mechanism effects on the brain. To gain insight into the neurological mechanisms involved in Anapanasati meditation, we measured the alterations of regional cerebral glucose metabolism during Anapanasati meditation using positron-emission tomography/computed tomography (PET/CT) and electroencephalography (EEG) analysis. This prospective study was conducted in six right-handed volunteer participants (two men, four women; aged: 32-67 years) who underwent18F-fluorodeoxyglucose (18F-FDG) PET/CT scans to compare the alterations of regional cerebral glucose metabolism during normal consciousness and Anapanasati meditation states. Spectral EEG analysis was performed throughout the investigations. Statistical parametric mapping was used for the18F-FDG PET/CT image analyses. The visual analysis demonstrated moderate-to-marked increased metabolism in posterior cingulate cortex in all six patients, while mild-to-moderate increased uptake in the whole frontal lobe was also observed in four patients and precuneus in four patients. Meanwhile, the semiquantitative analysis yielded an increase of regional cerebral glucose metabolism in the right mid-to-posterior cingulate gyrus (P < 0.000), with visible alpha waves on the frontal of the EEG findings. Our semiquantitative analysis showed a significantly increased metabolism only in the posterior cingulate cortex, but visually, there was also an increased metabolism in the whole frontal lobe in most of the patients correlating with EEG findings.

30 March 2021 in World Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
CCChotipanich Chanisa
Chotipanich Chanisa
NMNivorn Monchaya
Nivorn Monchaya
KAKunawudhi Anchisa
Kunawudhi Anchisa
PCPromteangtrong Chetsadaporn
Promteangtrong Chetsadaporn
JAJantarato Attapon
Jantarato Attapon
This study aims to determine the deposition of11C-Pittsburgh compound B (11C-PiB) and18F-THK 5351 using a normal database of the optimal cut-off-points for standardized uptake value ratios (SUVRs) in Alzheimer's disease (AD) patients. Sixteen AD patients and 24 cognitively normal individuals were enrolled in this study. The optimal cutoff points for the SUVR from the normal database were used for quantitative analysis. P-mod software with the Automated Anatomical Labeling merged atlas was employed to generate automatic volumes of interest to identify different brain regions, and the SUVRs of AD patients were compared with those of the age-matched normal controls. The correlation between PiB and THK5351 deposition at matching brain regions was identified. The mean regional11C-PiB SUVRs of the AD patients were significantly higher than the healthy controls (P < 0.05). The11C-PiB SUVR cut-offs were 1.46–1.81, with sensitivity ranging from 81.25% to 93.75% and specificity of 100%. The mean SUVRs of18F-THK 5351 in various regions were also significantly higher in the AD patients than in the healthy controls (P < 0.05). The inferior temporal gyrus yielded an optimum SUVR cut-off-points of 1.5 with 80% sensitivity and 83.33% specificity. The correlation of PiB and THK5351 SUVR was reported at precuneus, parietal, and occipital brain areas, with spearman's rho of 0.67, 0.66, and 0.72, respectively. Our findings allow determination of the SUVRs of11C-PiB and18F-THK-5351 amyloid and tau positron emission tomography tracers for clinical use, according to the normal database of the optimal cut-off-points for SUVRs in AD patients.

1 January 2021
Verified
Journal Article
Closed access
CCChanisa Chotipanich
Chanisa Chotipanich
SKSupaporn Kongthai
Supaporn Kongthai
AKAnchisa Kunawudhi
Anchisa Kunawudhi
CPChetsadaporn Promteangtrong
Chetsadaporn Promteangtrong
AJAttapon Jantarato
Attapon Jantarato